CD8A and neoplasm: These results reveal that LAMP3+ DCs are associated with T cell dysfunction; specifically, LAMP3+ DCs can inhibit CD8+ T cell function in the TME via the CD274/PDCD1LG2-PDCD1 axis or by recruiting Treg cells into the tumor.